Dompé Farmaceutici S.p.a.

Dompe Pha.r.ma S.p.a.

Dompe S.p.a.

Other

Children's Medical Center Corporation

Domp&eacute; S.p.a.

Dompe&prime; S.p.a

Marcello Allegretti

Maria Candida Cesta

Riccardo Bertini

Cinzia Bizzarri

Francesco Colotta

Andrea Aramini

Alessio Moriconi

Carmelo A Gandolfi

Gianfranco Caselli

Gianluca Bianchini

Laura Brandolini

Andrea Beccari

Marco Mantovanini

Vilma Sabbatini

Janete Peloia Barroso Gandolfi, Legal Representative

Giulio Agostino Gandolfi, Legal Representative

Maria Carla Gandolfi, Legal Representative

Arrigo Aldo Gandolfi, Legal Representative

Paolo Fiorina

Andrea Vergani

Vito Di Cioccio

Luisa Daffonchio

Roberto Curti

Luca Nicolini

Valerio Berdini

Stefano Porzio

Roberto Bassi

Marica Gemei

Marco Mosca

Ginfranco Caselli

Flavio Mantelli

Lorenzo Piemonti

Gaetano Clavenna

Samuele Lillini

Patrizia Angelico

Pier Adelchi Ruffini

Luigi Pellegrini

Gabriella Melillo

Simonetta Fiorentino

Thiago Mattar Cunha

Mauro Martins Teixeira

Mara Tomassetti

Marla Candida Cesta

Fracesco Colotta

Giuseppe Nano

The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.

Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use

The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.

IL-17A binding peptides and medical uses thereof

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.

IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the dipeptide L-Alanyl-L-alanine and their use for improving the performance and recovery during physical activity and for the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions.

Composition containing branched-chain amino acids

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), also including IC/PBS and/or OAB induced by anticancer therapy. Methods of treatment and/or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.

IL-8 inihibitors for use in the treatment of some urological disorders

The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of secondary bacterial infections, preferably secondary respiratory infections.

IL-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections

The present invention relates to C5aR inhibitor compounds, preferably C5aR noncompetitive allosteric inhibitors, useful in the treatment and/or prevention of chemotherapy-induced iatrogenic pain (CIIP).

C5aR inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.

Prevention and treatment of diabetic nephropathy

The use of sulfonamides of formula (I) wherein R and Rare as defined in the description, for the preparation of medicaments for the prevention of diabetes, in particular of type-1 diabetes is herein disclosed.

Sulfonamides for the prevention of diabetes

(R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes.

Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

The compounds of formula (I): where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia and reperfusion.

Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases

Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them

The use of sulfonamides of formula (I) wherein R and Rare as defined in the description, for the preparation of medicaments for the prevention of diabetes, in particular of type-1 diabetes is herein disclosed. 

Growing community of inventors

L'Aquila, Italy

Marcello Allegretti